Holler Seth D, Smith Sara Moran
WVU Medicine, Morgantown, WV, USA.
Allina Health, Minneapolis, MN, USA.
J Oncol Pharm Pract. 2025 Apr;31(3):488-494. doi: 10.1177/10781552251315146. Epub 2025 Feb 17.
ObjectiveTo provide a practical approach to pharmacists regarding the safe and effective use of nadofaragene firadenovec.Data sourcesClinical study data and pharmacist experience in institutional settings.Data summaryThis review article discusses the role of pharmacists caring for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) receiving nadofaragene firadenovec. Pharmacist roles in a multidisciplinary care team are described and involve considerations surrounding nadofaragene firadenovec, including its mechanism of action, indication, handling, storage, administration, adverse event profile, disposal, counseling, and other practical points.ConclusionsPharmacists are positioned to be key contributors to the care team regarding the effective use of nadofaragene firadenovec. Further awareness and education will continue to optimize the clinical use of nadofaragene firadenovec in the high-risk BCG-unresponsive NMIBC setting.
目的
为药剂师提供一种关于安全有效使用纳多福基因法瑞地诺韦的实用方法。
数据来源
临床研究数据以及机构环境中药剂师的经验。
数据总结
这篇综述文章讨论了药剂师在护理接受纳多福基因法瑞地诺韦治疗的卡介苗(BCG)无反应性非肌肉浸润性膀胱癌(NMIBC)患者中的作用。描述了药剂师在多学科护理团队中的角色,包括围绕纳多福基因法瑞地诺韦的考虑因素,如其作用机制、适应症、处理、储存、给药、不良事件概况、处置、咨询以及其他实际要点。
结论
药剂师有能力成为护理团队中有效使用纳多福基因法瑞地诺韦的关键贡献者。进一步提高认识和开展教育将继续优化纳多福基因法瑞地诺韦在高风险BCG无反应性NMIBC环境中的临床应用。